Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE).
Identifieur interne : 000750 ( Main/Exploration ); précédent : 000749; suivant : 000751Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE).
Auteurs : Sibylle Loibl [Allemagne] ; Lorena De La Pena [Espagne] ; Valentina Nekljudova [Allemagne] ; Dimitrios Zardavas [Belgique] ; Stefan Michiels [France] ; Carsten Denkert [Allemagne] ; Mahdi Rezai [Allemagne] ; Bego A Bermejo [Espagne] ; Michael Untch [Allemagne] ; Soo Chin Lee [Singapour] ; Sabine Turri [France] ; Patrick Urban [Suisse] ; Sherko Kümmel [Allemagne] ; Guenther Steger [Autriche] ; Andrea Gombos [Belgique] ; Michael Lux [Allemagne] ; Martine J. Piccart [Belgique] ; Gunter Von Minckwitz [Allemagne] ; José Baselga [États-Unis] ; Sherene Loi [Australie]Source :
- European journal of cancer (Oxford, England : 1990) [ 1879-0852 ] ; 2017.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Aminopyridines (administration et posologie), Aminopyridines (effets indésirables), Antigène KI-67 (métabolisme), Arrêt précoce d'essais cliniques, Australie, Biopsie, Europe, Facteurs temps, Femelle, Humains, Inhibiteurs de protéines kinases (administration et posologie), Inhibiteurs de protéines kinases (effets indésirables), Lymphocytes TIL (), Lésions hépatiques dues aux substances (étiologie), Marqueurs biologiques tumoraux (antagonistes et inhibiteurs), Marqueurs biologiques tumoraux (génétique), Marqueurs biologiques tumoraux (métabolisme), Morpholines (administration et posologie), Morpholines (effets indésirables), Mutation, Méthode en double aveugle, Paclitaxel (administration et posologie), Paclitaxel (effets indésirables), Phosphatidylinositol 3-kinases de classe I (antagonistes et inhibiteurs), Phosphatidylinositol 3-kinases de classe I (génétique), Phosphatidylinositol 3-kinases de classe I (métabolisme), Protocoles de polychimiothérapie antinéoplasique (effets indésirables), Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique), Récepteur ErbB-2 (antagonistes et inhibiteurs), Récepteur ErbB-2 (métabolisme), Résultat thérapeutique, Sujet âgé, Traitement médicamenteux adjuvant, Traitement néoadjuvant (effets indésirables), Trastuzumab (administration et posologie), Trastuzumab (effets indésirables), Tumeurs du sein (anatomopathologie), Tumeurs du sein (enzymologie), Tumeurs du sein (traitement médicamenteux).
- MESH :
- administration et posologie : Aminopyridines, Inhibiteurs de protéines kinases, Morpholines, Paclitaxel, Trastuzumab.
- anatomopathologie : Tumeurs du sein.
- antagonistes et inhibiteurs : Marqueurs biologiques tumoraux, Phosphatidylinositol 3-kinases de classe I, Récepteur ErbB-2.
- effets indésirables : Aminopyridines, Inhibiteurs de protéines kinases, Morpholines, Paclitaxel, Protocoles de polychimiothérapie antinéoplasique, Traitement néoadjuvant, Trastuzumab.
- enzymologie : Tumeurs du sein.
- génétique : Marqueurs biologiques tumoraux, Phosphatidylinositol 3-kinases de classe I.
- métabolisme : Antigène KI-67, Marqueurs biologiques tumoraux, Phosphatidylinositol 3-kinases de classe I, Récepteur ErbB-2.
- traitement médicamenteux : Tumeurs du sein.
- usage thérapeutique : Protocoles de polychimiothérapie antinéoplasique.
- étiologie : Lésions hépatiques dues aux substances.
- Adulte, Adulte d'âge moyen, Arrêt précoce d'essais cliniques, Australie, Biopsie, Europe, Facteurs temps, Femelle, Humains, Lymphocytes TIL, Mutation, Méthode en double aveugle, Résultat thérapeutique, Sujet âgé, Traitement médicamenteux adjuvant.
English descriptors
- KwdEn :
- Adult, Aged, Aminopyridines (administration & dosage), Aminopyridines (adverse effects), Antineoplastic Combined Chemotherapy Protocols (adverse effects), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Australia, Biomarkers, Tumor (antagonists & inhibitors), Biomarkers, Tumor (genetics), Biomarkers, Tumor (metabolism), Biopsy, Breast Neoplasms (drug therapy), Breast Neoplasms (enzymology), Breast Neoplasms (pathology), Chemical and Drug Induced Liver Injury (etiology), Chemotherapy, Adjuvant, Class I Phosphatidylinositol 3-Kinases (antagonists & inhibitors), Class I Phosphatidylinositol 3-Kinases (genetics), Class I Phosphatidylinositol 3-Kinases (metabolism), Double-Blind Method, Early Termination of Clinical Trials, Europe, Female, Humans, Ki-67 Antigen (metabolism), Lymphocytes, Tumor-Infiltrating (drug effects), Middle Aged, Morpholines (administration & dosage), Morpholines (adverse effects), Mutation, Neoadjuvant Therapy (adverse effects), Paclitaxel (administration & dosage), Paclitaxel (adverse effects), Protein Kinase Inhibitors (administration & dosage), Protein Kinase Inhibitors (adverse effects), Receptor, ErbB-2 (antagonists & inhibitors), Receptor, ErbB-2 (metabolism), Time Factors, Trastuzumab (administration & dosage), Trastuzumab (adverse effects), Treatment Outcome.
- MESH :
- chemical , administration & dosage : Aminopyridines, Morpholines, Paclitaxel, Protein Kinase Inhibitors, Trastuzumab.
- chemical , adverse effects : Aminopyridines, Morpholines, Paclitaxel, Protein Kinase Inhibitors, Trastuzumab.
- adverse effects : Antineoplastic Combined Chemotherapy Protocols, Neoadjuvant Therapy.
- chemical , antagonists & inhibitors : Biomarkers, Tumor, Class I Phosphatidylinositol 3-Kinases, Receptor, ErbB-2.
- drug effects : Lymphocytes, Tumor-Infiltrating.
- drug therapy : Breast Neoplasms.
- enzymology : Breast Neoplasms.
- etiology : Chemical and Drug Induced Liver Injury.
- chemical , genetics : Biomarkers, Tumor, Class I Phosphatidylinositol 3-Kinases.
- chemical , metabolism : Biomarkers, Tumor, Class I Phosphatidylinositol 3-Kinases, Ki-67 Antigen, Receptor, ErbB-2.
- pathology : Breast Neoplasms.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Adult, Aged, Australia, Biopsy, Chemotherapy, Adjuvant, Double-Blind Method, Early Termination of Clinical Trials, Europe, Female, Humans, Middle Aged, Mutation, Time Factors, Treatment Outcome.
Abstract
The Neoadjuvant PI3K inhibition in HER2 OverExpressing Breast cancEr (NeoPHOEBE) trial evaluated the efficacy and safety of buparlisib, a pan-phosphatidylinositol 3-kinase (PI3K) inhibitor, plus trastuzumab and paclitaxel as neoadjuvant treatment for human epidermal growth factor receptor-2 positive (HER2+) breast cancer.
DOI: 10.1016/j.ejca.2017.08.020
PubMed: 28923573
Affiliations:
- Allemagne, Australie, Autriche, Belgique, Espagne, France, Singapour, Suisse, États-Unis
- Berlin, Catalogne, Région de Bruxelles-Capitale, État de New York
- Barcelone, Berlin, Bruxelles
- Université libre de Bruxelles
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000176
- to stream PubMed, to step Curation: 000176
- to stream PubMed, to step Checkpoint: 000176
- to stream Ncbi, to step Merge: 004E85
- to stream Ncbi, to step Curation: 004E85
- to stream Ncbi, to step Checkpoint: 004E85
- to stream Main, to step Merge: 000745
- to stream Main, to step Curation: 000750
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE).</title><author><name sortKey="Loibl, Sibylle" sort="Loibl, Sibylle" uniqKey="Loibl S" first="Sibylle" last="Loibl">Sibylle Loibl</name><affiliation wicri:level="1"><nlm:affiliation>German Breast Group, Neu-Isenburg, Germany; Sana-Klinikum Offenbach, Germany. Electronic address: Sibylle.Loibl@gbg.de.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>German Breast Group, Neu-Isenburg, Germany; Sana-Klinikum Offenbach</wicri:regionArea><wicri:noRegion>Germany; Sana-Klinikum Offenbach</wicri:noRegion><wicri:noRegion>Germany; Sana-Klinikum Offenbach</wicri:noRegion><wicri:noRegion>Germany; Sana-Klinikum Offenbach</wicri:noRegion></affiliation></author><author><name sortKey="De La Pena, Lorena" sort="De La Pena, Lorena" uniqKey="De La Pena L" first="Lorena" last="De La Pena">Lorena De La Pena</name><affiliation wicri:level="3"><nlm:affiliation>SOLTI Breast Cancer Research Group, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>SOLTI Breast Cancer Research Group, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Nekljudova, Valentina" sort="Nekljudova, Valentina" uniqKey="Nekljudova V" first="Valentina" last="Nekljudova">Valentina Nekljudova</name><affiliation wicri:level="1"><nlm:affiliation>German Breast Group, Neu-Isenburg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>German Breast Group, Neu-Isenburg</wicri:regionArea><wicri:noRegion>Neu-Isenburg</wicri:noRegion><wicri:noRegion>Neu-Isenburg</wicri:noRegion><wicri:noRegion>Neu-Isenburg</wicri:noRegion></affiliation></author><author><name sortKey="Zardavas, Dimitrios" sort="Zardavas, Dimitrios" uniqKey="Zardavas D" first="Dimitrios" last="Zardavas">Dimitrios Zardavas</name><affiliation wicri:level="3"><nlm:affiliation>Breast International Group, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Breast International Group, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Michiels, Stefan" sort="Michiels, Stefan" uniqKey="Michiels S" first="Stefan" last="Michiels">Stefan Michiels</name><affiliation wicri:level="1"><nlm:affiliation>Gustave Roussy, Service de Biostatistique et d'Epidémiologie, Villejuif, France; CESP, Inserm U1018, Univ. Paris Sud, Univ. Paris-Saclay, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Gustave Roussy, Service de Biostatistique et d'Epidémiologie, Villejuif, France; CESP, Inserm U1018, Univ. Paris Sud, Univ. Paris-Saclay, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><wicri:noRegion>Villejuif</wicri:noRegion></affiliation></author><author><name sortKey="Denkert, Carsten" sort="Denkert, Carsten" uniqKey="Denkert C" first="Carsten" last="Denkert">Carsten Denkert</name><affiliation wicri:level="3"><nlm:affiliation>Institute of Pathology, Charité University Hospital, Berlin, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institute of Pathology, Charité University Hospital, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Rezai, Mahdi" sort="Rezai, Mahdi" uniqKey="Rezai M" first="Mahdi" last="Rezai">Mahdi Rezai</name><affiliation wicri:level="1"><nlm:affiliation>Luisenkrankenhaus Düsseldorf, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Luisenkrankenhaus Düsseldorf</wicri:regionArea></affiliation></author><author><name sortKey="Bermejo, Bego A" sort="Bermejo, Bego A" uniqKey="Bermejo B" first="Bego A" last="Bermejo">Bego A Bermejo</name><affiliation wicri:level="1"><nlm:affiliation>Hospital Clinico Universitario de Valencia, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Clinico Universitario de Valencia</wicri:regionArea></affiliation></author><author><name sortKey="Untch, Michael" sort="Untch, Michael" uniqKey="Untch M" first="Michael" last="Untch">Michael Untch</name><affiliation wicri:level="3"><nlm:affiliation>Helios Klinikum Berlin-Buch, Department of Obstetrics and Gynaecology, Berlin, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Helios Klinikum Berlin-Buch, Department of Obstetrics and Gynaecology, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Lee, Soo Chin" sort="Lee, Soo Chin" uniqKey="Lee S" first="Soo Chin" last="Lee">Soo Chin Lee</name><affiliation wicri:level="1"><nlm:affiliation>Department of Haematology-Oncology, National University Cancer Institute, Singapore.</nlm:affiliation><country xml:lang="fr">Singapour</country><wicri:regionArea>Department of Haematology-Oncology, National University Cancer Institute</wicri:regionArea><wicri:noRegion>National University Cancer Institute</wicri:noRegion></affiliation></author><author><name sortKey="Turri, Sabine" sort="Turri, Sabine" uniqKey="Turri S" first="Sabine" last="Turri">Sabine Turri</name><affiliation wicri:level="1"><nlm:affiliation>Novartis Pharma SAS, Rueil Malmaison, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Novartis Pharma SAS, Rueil Malmaison</wicri:regionArea><wicri:noRegion>Rueil Malmaison</wicri:noRegion><wicri:noRegion>Rueil Malmaison</wicri:noRegion></affiliation></author><author><name sortKey="Urban, Patrick" sort="Urban, Patrick" uniqKey="Urban P" first="Patrick" last="Urban">Patrick Urban</name><affiliation wicri:level="1"><nlm:affiliation>Novartis Pharma AG, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Kummel, Sherko" sort="Kummel, Sherko" uniqKey="Kummel S" first="Sherko" last="Kümmel">Sherko Kümmel</name><affiliation wicri:level="1"><nlm:affiliation>Kliniken Essen-Mitte, Essen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Kliniken Essen-Mitte, Essen</wicri:regionArea><wicri:noRegion>Essen</wicri:noRegion><wicri:noRegion>Essen</wicri:noRegion><wicri:noRegion>Essen</wicri:noRegion></affiliation></author><author><name sortKey="Steger, Guenther" sort="Steger, Guenther" uniqKey="Steger G" first="Guenther" last="Steger">Guenther Steger</name><affiliation wicri:level="1"><nlm:affiliation>Department of Internal Medicine I, Division of Oncology, Medical University of Vienna, Austria; Comprehensive Cancer Center Vienna, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Internal Medicine I, Division of Oncology, Medical University of Vienna, Austria; Comprehensive Cancer Center Vienna</wicri:regionArea><wicri:noRegion>Austria; Comprehensive Cancer Center Vienna</wicri:noRegion></affiliation></author><author><name sortKey="Gombos, Andrea" sort="Gombos, Andrea" uniqKey="Gombos A" first="Andrea" last="Gombos">Andrea Gombos</name><affiliation wicri:level="4"><nlm:affiliation>Université Libre de Bruxelles, Institut Jules Rue Héger-Bordet 1, Medical Oncology Clinic, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Université Libre de Bruxelles, Institut Jules Rue Héger-Bordet 1, Medical Oncology Clinic</wicri:regionArea><orgName type="university">Université libre de Bruxelles</orgName><placeName><settlement type="city">Bruxelles</settlement><region type="region" nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Lux, Michael" sort="Lux, Michael" uniqKey="Lux M" first="Michael" last="Lux">Michael Lux</name><affiliation wicri:level="1"><nlm:affiliation>University Breast Centre of Franconia, OBGYN Department, University Hospital Erlangen, CCC Erlangen-EMN, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>University Breast Centre of Franconia, OBGYN Department, University Hospital Erlangen, CCC Erlangen-EMN</wicri:regionArea><wicri:noRegion>CCC Erlangen-EMN</wicri:noRegion><wicri:noRegion>CCC Erlangen-EMN</wicri:noRegion><wicri:noRegion>CCC Erlangen-EMN</wicri:noRegion></affiliation></author><author><name sortKey="Piccart, Martine J" sort="Piccart, Martine J" uniqKey="Piccart M" first="Martine J" last="Piccart">Martine J. Piccart</name><affiliation wicri:level="1"><nlm:affiliation>Breast International Group, Brussels, Belgium; Université Libre de Bruxelles, Institut Jules Rue Héger-Bordet 1, Medical Oncology Clinic, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Breast International Group, Brussels, Belgium; Université Libre de Bruxelles, Institut Jules Rue Héger-Bordet 1, Medical Oncology Clinic</wicri:regionArea><wicri:noRegion>Medical Oncology Clinic</wicri:noRegion></affiliation></author><author><name sortKey="Von Minckwitz, Gunter" sort="Von Minckwitz, Gunter" uniqKey="Von Minckwitz G" first="Gunter" last="Von Minckwitz">Gunter Von Minckwitz</name><affiliation wicri:level="1"><nlm:affiliation>German Breast Group, Neu-Isenburg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>German Breast Group, Neu-Isenburg</wicri:regionArea><wicri:noRegion>Neu-Isenburg</wicri:noRegion><wicri:noRegion>Neu-Isenburg</wicri:noRegion><wicri:noRegion>Neu-Isenburg</wicri:noRegion></affiliation></author><author><name sortKey="Baselga, Jose" sort="Baselga, Jose" uniqKey="Baselga J" first="José" last="Baselga">José Baselga</name><affiliation wicri:level="2"><nlm:affiliation>SOLTI Breast Cancer Research Group, Barcelona, Spain; Memorial Sloan-Kettering Cancer Center, New York, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>SOLTI Breast Cancer Research Group, Barcelona, Spain; Memorial Sloan-Kettering Cancer Center, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Loi, Sherene" sort="Loi, Sherene" uniqKey="Loi S" first="Sherene" last="Loi">Sherene Loi</name><affiliation wicri:level="1"><nlm:affiliation>Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Australian New Zealand Breast Cancer Trials Group (ANZBCTG), Newcastle, Australia. Electronic address: sherene.loi@petermac.org.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Australian New Zealand Breast Cancer Trials Group (ANZBCTG), Newcastle</wicri:regionArea><wicri:noRegion>Newcastle</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28923573</idno><idno type="pmid">28923573</idno><idno type="doi">10.1016/j.ejca.2017.08.020</idno><idno type="wicri:Area/PubMed/Corpus">000176</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000176</idno><idno type="wicri:Area/PubMed/Curation">000176</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000176</idno><idno type="wicri:Area/PubMed/Checkpoint">000176</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000176</idno><idno type="wicri:Area/Ncbi/Merge">004E85</idno><idno type="wicri:Area/Ncbi/Curation">004E85</idno><idno type="wicri:Area/Ncbi/Checkpoint">004E85</idno><idno type="wicri:Area/Main/Merge">000745</idno><idno type="wicri:Area/Main/Curation">000750</idno><idno type="wicri:Area/Main/Exploration">000750</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE).</title><author><name sortKey="Loibl, Sibylle" sort="Loibl, Sibylle" uniqKey="Loibl S" first="Sibylle" last="Loibl">Sibylle Loibl</name><affiliation wicri:level="1"><nlm:affiliation>German Breast Group, Neu-Isenburg, Germany; Sana-Klinikum Offenbach, Germany. Electronic address: Sibylle.Loibl@gbg.de.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>German Breast Group, Neu-Isenburg, Germany; Sana-Klinikum Offenbach</wicri:regionArea><wicri:noRegion>Germany; Sana-Klinikum Offenbach</wicri:noRegion><wicri:noRegion>Germany; Sana-Klinikum Offenbach</wicri:noRegion><wicri:noRegion>Germany; Sana-Klinikum Offenbach</wicri:noRegion></affiliation></author><author><name sortKey="De La Pena, Lorena" sort="De La Pena, Lorena" uniqKey="De La Pena L" first="Lorena" last="De La Pena">Lorena De La Pena</name><affiliation wicri:level="3"><nlm:affiliation>SOLTI Breast Cancer Research Group, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>SOLTI Breast Cancer Research Group, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Nekljudova, Valentina" sort="Nekljudova, Valentina" uniqKey="Nekljudova V" first="Valentina" last="Nekljudova">Valentina Nekljudova</name><affiliation wicri:level="1"><nlm:affiliation>German Breast Group, Neu-Isenburg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>German Breast Group, Neu-Isenburg</wicri:regionArea><wicri:noRegion>Neu-Isenburg</wicri:noRegion><wicri:noRegion>Neu-Isenburg</wicri:noRegion><wicri:noRegion>Neu-Isenburg</wicri:noRegion></affiliation></author><author><name sortKey="Zardavas, Dimitrios" sort="Zardavas, Dimitrios" uniqKey="Zardavas D" first="Dimitrios" last="Zardavas">Dimitrios Zardavas</name><affiliation wicri:level="3"><nlm:affiliation>Breast International Group, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Breast International Group, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Michiels, Stefan" sort="Michiels, Stefan" uniqKey="Michiels S" first="Stefan" last="Michiels">Stefan Michiels</name><affiliation wicri:level="1"><nlm:affiliation>Gustave Roussy, Service de Biostatistique et d'Epidémiologie, Villejuif, France; CESP, Inserm U1018, Univ. Paris Sud, Univ. Paris-Saclay, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Gustave Roussy, Service de Biostatistique et d'Epidémiologie, Villejuif, France; CESP, Inserm U1018, Univ. Paris Sud, Univ. Paris-Saclay, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><wicri:noRegion>Villejuif</wicri:noRegion></affiliation></author><author><name sortKey="Denkert, Carsten" sort="Denkert, Carsten" uniqKey="Denkert C" first="Carsten" last="Denkert">Carsten Denkert</name><affiliation wicri:level="3"><nlm:affiliation>Institute of Pathology, Charité University Hospital, Berlin, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institute of Pathology, Charité University Hospital, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Rezai, Mahdi" sort="Rezai, Mahdi" uniqKey="Rezai M" first="Mahdi" last="Rezai">Mahdi Rezai</name><affiliation wicri:level="1"><nlm:affiliation>Luisenkrankenhaus Düsseldorf, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Luisenkrankenhaus Düsseldorf</wicri:regionArea></affiliation></author><author><name sortKey="Bermejo, Bego A" sort="Bermejo, Bego A" uniqKey="Bermejo B" first="Bego A" last="Bermejo">Bego A Bermejo</name><affiliation wicri:level="1"><nlm:affiliation>Hospital Clinico Universitario de Valencia, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Clinico Universitario de Valencia</wicri:regionArea></affiliation></author><author><name sortKey="Untch, Michael" sort="Untch, Michael" uniqKey="Untch M" first="Michael" last="Untch">Michael Untch</name><affiliation wicri:level="3"><nlm:affiliation>Helios Klinikum Berlin-Buch, Department of Obstetrics and Gynaecology, Berlin, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Helios Klinikum Berlin-Buch, Department of Obstetrics and Gynaecology, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Lee, Soo Chin" sort="Lee, Soo Chin" uniqKey="Lee S" first="Soo Chin" last="Lee">Soo Chin Lee</name><affiliation wicri:level="1"><nlm:affiliation>Department of Haematology-Oncology, National University Cancer Institute, Singapore.</nlm:affiliation><country xml:lang="fr">Singapour</country><wicri:regionArea>Department of Haematology-Oncology, National University Cancer Institute</wicri:regionArea><wicri:noRegion>National University Cancer Institute</wicri:noRegion></affiliation></author><author><name sortKey="Turri, Sabine" sort="Turri, Sabine" uniqKey="Turri S" first="Sabine" last="Turri">Sabine Turri</name><affiliation wicri:level="1"><nlm:affiliation>Novartis Pharma SAS, Rueil Malmaison, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Novartis Pharma SAS, Rueil Malmaison</wicri:regionArea><wicri:noRegion>Rueil Malmaison</wicri:noRegion><wicri:noRegion>Rueil Malmaison</wicri:noRegion></affiliation></author><author><name sortKey="Urban, Patrick" sort="Urban, Patrick" uniqKey="Urban P" first="Patrick" last="Urban">Patrick Urban</name><affiliation wicri:level="1"><nlm:affiliation>Novartis Pharma AG, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Kummel, Sherko" sort="Kummel, Sherko" uniqKey="Kummel S" first="Sherko" last="Kümmel">Sherko Kümmel</name><affiliation wicri:level="1"><nlm:affiliation>Kliniken Essen-Mitte, Essen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Kliniken Essen-Mitte, Essen</wicri:regionArea><wicri:noRegion>Essen</wicri:noRegion><wicri:noRegion>Essen</wicri:noRegion><wicri:noRegion>Essen</wicri:noRegion></affiliation></author><author><name sortKey="Steger, Guenther" sort="Steger, Guenther" uniqKey="Steger G" first="Guenther" last="Steger">Guenther Steger</name><affiliation wicri:level="1"><nlm:affiliation>Department of Internal Medicine I, Division of Oncology, Medical University of Vienna, Austria; Comprehensive Cancer Center Vienna, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Internal Medicine I, Division of Oncology, Medical University of Vienna, Austria; Comprehensive Cancer Center Vienna</wicri:regionArea><wicri:noRegion>Austria; Comprehensive Cancer Center Vienna</wicri:noRegion></affiliation></author><author><name sortKey="Gombos, Andrea" sort="Gombos, Andrea" uniqKey="Gombos A" first="Andrea" last="Gombos">Andrea Gombos</name><affiliation wicri:level="4"><nlm:affiliation>Université Libre de Bruxelles, Institut Jules Rue Héger-Bordet 1, Medical Oncology Clinic, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Université Libre de Bruxelles, Institut Jules Rue Héger-Bordet 1, Medical Oncology Clinic</wicri:regionArea><orgName type="university">Université libre de Bruxelles</orgName><placeName><settlement type="city">Bruxelles</settlement><region type="region" nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Lux, Michael" sort="Lux, Michael" uniqKey="Lux M" first="Michael" last="Lux">Michael Lux</name><affiliation wicri:level="1"><nlm:affiliation>University Breast Centre of Franconia, OBGYN Department, University Hospital Erlangen, CCC Erlangen-EMN, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>University Breast Centre of Franconia, OBGYN Department, University Hospital Erlangen, CCC Erlangen-EMN</wicri:regionArea><wicri:noRegion>CCC Erlangen-EMN</wicri:noRegion><wicri:noRegion>CCC Erlangen-EMN</wicri:noRegion><wicri:noRegion>CCC Erlangen-EMN</wicri:noRegion></affiliation></author><author><name sortKey="Piccart, Martine J" sort="Piccart, Martine J" uniqKey="Piccart M" first="Martine J" last="Piccart">Martine J. Piccart</name><affiliation wicri:level="1"><nlm:affiliation>Breast International Group, Brussels, Belgium; Université Libre de Bruxelles, Institut Jules Rue Héger-Bordet 1, Medical Oncology Clinic, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Breast International Group, Brussels, Belgium; Université Libre de Bruxelles, Institut Jules Rue Héger-Bordet 1, Medical Oncology Clinic</wicri:regionArea><wicri:noRegion>Medical Oncology Clinic</wicri:noRegion></affiliation></author><author><name sortKey="Von Minckwitz, Gunter" sort="Von Minckwitz, Gunter" uniqKey="Von Minckwitz G" first="Gunter" last="Von Minckwitz">Gunter Von Minckwitz</name><affiliation wicri:level="1"><nlm:affiliation>German Breast Group, Neu-Isenburg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>German Breast Group, Neu-Isenburg</wicri:regionArea><wicri:noRegion>Neu-Isenburg</wicri:noRegion><wicri:noRegion>Neu-Isenburg</wicri:noRegion><wicri:noRegion>Neu-Isenburg</wicri:noRegion></affiliation></author><author><name sortKey="Baselga, Jose" sort="Baselga, Jose" uniqKey="Baselga J" first="José" last="Baselga">José Baselga</name><affiliation wicri:level="2"><nlm:affiliation>SOLTI Breast Cancer Research Group, Barcelona, Spain; Memorial Sloan-Kettering Cancer Center, New York, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>SOLTI Breast Cancer Research Group, Barcelona, Spain; Memorial Sloan-Kettering Cancer Center, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Loi, Sherene" sort="Loi, Sherene" uniqKey="Loi S" first="Sherene" last="Loi">Sherene Loi</name><affiliation wicri:level="1"><nlm:affiliation>Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Australian New Zealand Breast Cancer Trials Group (ANZBCTG), Newcastle, Australia. Electronic address: sherene.loi@petermac.org.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Australian New Zealand Breast Cancer Trials Group (ANZBCTG), Newcastle</wicri:regionArea><wicri:noRegion>Newcastle</wicri:noRegion></affiliation></author></analytic><series><title level="j">European journal of cancer (Oxford, England : 1990)</title><idno type="eISSN">1879-0852</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aminopyridines (administration & dosage)</term><term>Aminopyridines (adverse effects)</term><term>Antineoplastic Combined Chemotherapy Protocols (adverse effects)</term><term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term><term>Australia</term><term>Biomarkers, Tumor (antagonists & inhibitors)</term><term>Biomarkers, Tumor (genetics)</term><term>Biomarkers, Tumor (metabolism)</term><term>Biopsy</term><term>Breast Neoplasms (drug therapy)</term><term>Breast Neoplasms (enzymology)</term><term>Breast Neoplasms (pathology)</term><term>Chemical and Drug Induced Liver Injury (etiology)</term><term>Chemotherapy, Adjuvant</term><term>Class I Phosphatidylinositol 3-Kinases (antagonists & inhibitors)</term><term>Class I Phosphatidylinositol 3-Kinases (genetics)</term><term>Class I Phosphatidylinositol 3-Kinases (metabolism)</term><term>Double-Blind Method</term><term>Early Termination of Clinical Trials</term><term>Europe</term><term>Female</term><term>Humans</term><term>Ki-67 Antigen (metabolism)</term><term>Lymphocytes, Tumor-Infiltrating (drug effects)</term><term>Middle Aged</term><term>Morpholines (administration & dosage)</term><term>Morpholines (adverse effects)</term><term>Mutation</term><term>Neoadjuvant Therapy (adverse effects)</term><term>Paclitaxel (administration & dosage)</term><term>Paclitaxel (adverse effects)</term><term>Protein Kinase Inhibitors (administration & dosage)</term><term>Protein Kinase Inhibitors (adverse effects)</term><term>Receptor, ErbB-2 (antagonists & inhibitors)</term><term>Receptor, ErbB-2 (metabolism)</term><term>Time Factors</term><term>Trastuzumab (administration & dosage)</term><term>Trastuzumab (adverse effects)</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Aminopyridines (administration et posologie)</term><term>Aminopyridines (effets indésirables)</term><term>Antigène KI-67 (métabolisme)</term><term>Arrêt précoce d'essais cliniques</term><term>Australie</term><term>Biopsie</term><term>Europe</term><term>Facteurs temps</term><term>Femelle</term><term>Humains</term><term>Inhibiteurs de protéines kinases (administration et posologie)</term><term>Inhibiteurs de protéines kinases (effets indésirables)</term><term>Lymphocytes TIL ()</term><term>Lésions hépatiques dues aux substances (étiologie)</term><term>Marqueurs biologiques tumoraux (antagonistes et inhibiteurs)</term><term>Marqueurs biologiques tumoraux (génétique)</term><term>Marqueurs biologiques tumoraux (métabolisme)</term><term>Morpholines (administration et posologie)</term><term>Morpholines (effets indésirables)</term><term>Mutation</term><term>Méthode en double aveugle</term><term>Paclitaxel (administration et posologie)</term><term>Paclitaxel (effets indésirables)</term><term>Phosphatidylinositol 3-kinases de classe I (antagonistes et inhibiteurs)</term><term>Phosphatidylinositol 3-kinases de classe I (génétique)</term><term>Phosphatidylinositol 3-kinases de classe I (métabolisme)</term><term>Protocoles de polychimiothérapie antinéoplasique (effets indésirables)</term><term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term><term>Récepteur ErbB-2 (antagonistes et inhibiteurs)</term><term>Récepteur ErbB-2 (métabolisme)</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Traitement médicamenteux adjuvant</term><term>Traitement néoadjuvant (effets indésirables)</term><term>Trastuzumab (administration et posologie)</term><term>Trastuzumab (effets indésirables)</term><term>Tumeurs du sein (anatomopathologie)</term><term>Tumeurs du sein (enzymologie)</term><term>Tumeurs du sein (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Aminopyridines</term><term>Morpholines</term><term>Paclitaxel</term><term>Protein Kinase Inhibitors</term><term>Trastuzumab</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Aminopyridines</term><term>Morpholines</term><term>Paclitaxel</term><term>Protein Kinase Inhibitors</term><term>Trastuzumab</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Aminopyridines</term><term>Inhibiteurs de protéines kinases</term><term>Morpholines</term><term>Paclitaxel</term><term>Trastuzumab</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term><term>Neoadjuvant Therapy</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Marqueurs biologiques tumoraux</term><term>Phosphatidylinositol 3-kinases de classe I</term><term>Récepteur ErbB-2</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Biomarkers, Tumor</term><term>Class I Phosphatidylinositol 3-Kinases</term><term>Receptor, ErbB-2</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Lymphocytes, Tumor-Infiltrating</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Aminopyridines</term><term>Inhibiteurs de protéines kinases</term><term>Morpholines</term><term>Paclitaxel</term><term>Protocoles de polychimiothérapie antinéoplasique</term><term>Traitement néoadjuvant</term><term>Trastuzumab</term></keywords><keywords scheme="MESH" qualifier="enzymologie" xml:lang="fr"><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Chemical and Drug Induced Liver Injury</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Biomarkers, Tumor</term><term>Class I Phosphatidylinositol 3-Kinases</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Marqueurs biologiques tumoraux</term><term>Phosphatidylinositol 3-kinases de classe I</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Biomarkers, Tumor</term><term>Class I Phosphatidylinositol 3-Kinases</term><term>Ki-67 Antigen</term><term>Receptor, ErbB-2</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Antigène KI-67</term><term>Marqueurs biologiques tumoraux</term><term>Phosphatidylinositol 3-kinases de classe I</term><term>Récepteur ErbB-2</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Protocoles de polychimiothérapie antinéoplasique</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Lésions hépatiques dues aux substances</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Australia</term><term>Biopsy</term><term>Chemotherapy, Adjuvant</term><term>Double-Blind Method</term><term>Early Termination of Clinical Trials</term><term>Europe</term><term>Female</term><term>Humans</term><term>Middle Aged</term><term>Mutation</term><term>Time Factors</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Arrêt précoce d'essais cliniques</term><term>Australie</term><term>Biopsie</term><term>Europe</term><term>Facteurs temps</term><term>Femelle</term><term>Humains</term><term>Lymphocytes TIL</term><term>Mutation</term><term>Méthode en double aveugle</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Traitement médicamenteux adjuvant</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The Neoadjuvant PI3K inhibition in HER2 OverExpressing Breast cancEr (NeoPHOEBE) trial evaluated the efficacy and safety of buparlisib, a pan-phosphatidylinositol 3-kinase (PI3K) inhibitor, plus trastuzumab and paclitaxel as neoadjuvant treatment for human epidermal growth factor receptor-2 positive (HER2+) breast cancer.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Autriche</li><li>Belgique</li><li>Espagne</li><li>France</li><li>Singapour</li><li>Suisse</li><li>États-Unis</li></country><region><li>Berlin</li><li>Catalogne</li><li>Région de Bruxelles-Capitale</li><li>État de New York</li></region><settlement><li>Barcelone</li><li>Berlin</li><li>Bruxelles</li></settlement><orgName><li>Université libre de Bruxelles</li></orgName></list><tree><country name="Allemagne"><noRegion><name sortKey="Loibl, Sibylle" sort="Loibl, Sibylle" uniqKey="Loibl S" first="Sibylle" last="Loibl">Sibylle Loibl</name></noRegion><name sortKey="Denkert, Carsten" sort="Denkert, Carsten" uniqKey="Denkert C" first="Carsten" last="Denkert">Carsten Denkert</name><name sortKey="Kummel, Sherko" sort="Kummel, Sherko" uniqKey="Kummel S" first="Sherko" last="Kümmel">Sherko Kümmel</name><name sortKey="Lux, Michael" sort="Lux, Michael" uniqKey="Lux M" first="Michael" last="Lux">Michael Lux</name><name sortKey="Nekljudova, Valentina" sort="Nekljudova, Valentina" uniqKey="Nekljudova V" first="Valentina" last="Nekljudova">Valentina Nekljudova</name><name sortKey="Rezai, Mahdi" sort="Rezai, Mahdi" uniqKey="Rezai M" first="Mahdi" last="Rezai">Mahdi Rezai</name><name sortKey="Untch, Michael" sort="Untch, Michael" uniqKey="Untch M" first="Michael" last="Untch">Michael Untch</name><name sortKey="Von Minckwitz, Gunter" sort="Von Minckwitz, Gunter" uniqKey="Von Minckwitz G" first="Gunter" last="Von Minckwitz">Gunter Von Minckwitz</name></country><country name="Espagne"><region name="Catalogne"><name sortKey="De La Pena, Lorena" sort="De La Pena, Lorena" uniqKey="De La Pena L" first="Lorena" last="De La Pena">Lorena De La Pena</name></region><name sortKey="Bermejo, Bego A" sort="Bermejo, Bego A" uniqKey="Bermejo B" first="Bego A" last="Bermejo">Bego A Bermejo</name></country><country name="Belgique"><region name="Région de Bruxelles-Capitale"><name sortKey="Zardavas, Dimitrios" sort="Zardavas, Dimitrios" uniqKey="Zardavas D" first="Dimitrios" last="Zardavas">Dimitrios Zardavas</name></region><name sortKey="Gombos, Andrea" sort="Gombos, Andrea" uniqKey="Gombos A" first="Andrea" last="Gombos">Andrea Gombos</name><name sortKey="Piccart, Martine J" sort="Piccart, Martine J" uniqKey="Piccart M" first="Martine J" last="Piccart">Martine J. Piccart</name></country><country name="France"><noRegion><name sortKey="Michiels, Stefan" sort="Michiels, Stefan" uniqKey="Michiels S" first="Stefan" last="Michiels">Stefan Michiels</name></noRegion><name sortKey="Turri, Sabine" sort="Turri, Sabine" uniqKey="Turri S" first="Sabine" last="Turri">Sabine Turri</name></country><country name="Singapour"><noRegion><name sortKey="Lee, Soo Chin" sort="Lee, Soo Chin" uniqKey="Lee S" first="Soo Chin" last="Lee">Soo Chin Lee</name></noRegion></country><country name="Suisse"><noRegion><name sortKey="Urban, Patrick" sort="Urban, Patrick" uniqKey="Urban P" first="Patrick" last="Urban">Patrick Urban</name></noRegion></country><country name="Autriche"><noRegion><name sortKey="Steger, Guenther" sort="Steger, Guenther" uniqKey="Steger G" first="Guenther" last="Steger">Guenther Steger</name></noRegion></country><country name="États-Unis"><region name="État de New York"><name sortKey="Baselga, Jose" sort="Baselga, Jose" uniqKey="Baselga J" first="José" last="Baselga">José Baselga</name></region></country><country name="Australie"><noRegion><name sortKey="Loi, Sherene" sort="Loi, Sherene" uniqKey="Loi S" first="Sherene" last="Loi">Sherene Loi</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000750 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000750 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:28923573
|texte= Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE).
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:28923573" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |